Skip to main content
Premium Trial:

Request an Annual Quote

GeneSoft Gets Another $5.5M from Department of Defense for DNA-Targeting Antibiotics

NEW YORK, April 18 - GeneSoft Pharmaceuticals said today that it has received another $5.5 million in funding from the US Department of Defense to develop small molecule drugs that target specific DNA sequences in biowarfare agents.


The funding is in addition to $15.3 million the South San Francisco-based company has already received over the last four years for an ongoing contract with the Defense Advanced Research Project Agency and the US Army.


GeneSoft, which licenses its DNA-binding technology from the University of Geneva in Switzerland, develops novel anti-infective agents that interfere with gene expression and DNA replication by binding to specific DNA sequences.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.